Cost-effectiveness of England's national 'Safe At Home' scheme for reducing hospital admissions for unintentional injury in children aged under 5.


Journal

Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention
ISSN: 1475-5785
Titre abrégé: Inj Prev
Pays: England
ID NLM: 9510056

Informations de publication

Date de publication:
04 2023
Historique:
received: 07 07 2022
accepted: 06 11 2022
pubmed: 6 1 2023
medline: 24 3 2023
entrez: 5 1 2023
Statut: ppublish

Résumé

Injuries in children aged under 5 years most commonly occur in the home and disproportionately affect those living in the most disadvantaged communities. The 'Safe at Home' (SAH) national home safety equipment scheme, which ran in England between 2009 and 2011, has been shown to reduce injury-related hospital admissions, but there is little evidence of cost-effectiveness. Cost-effectiveness analysis from a health and local government perspective. Measures were the incremental cost-effectiveness ratio per hospital admission averted (ICER) and cost-offset ratio (COR), comparing SAH expenditure to savings in admission expenditure. The study period was split into three periods: T1 (years 0-2, implementation); T2 (years 3-4) and T3 (years 5-6). Analyses were conducted for T2 versus T1 and T3 versus T1. Total cost of SAH was £9 518 066. 202 223 hospital admissions in the children occurred during T1-3, costing £3 320 000. Comparing T3 to T1 SAH reduced admission expenditure by £924 per month per local authority and monthly admission rates by 0.5 per local authority per month compared with control areas. ICER per admission averted was £4209 for T3 versus T1, with a COR of £0.29, suggesting that 29p was returned in savings on admission expenditure for every pound spent on SAH. SAH was effective at reducing hospital admissions due to injury and did result in some cost recovery when taking into admissions only. Further analysis of its cost-effectiveness, including emergency healthcare, primary care attendances and wider societal costs, is likely to improve the return on investment further.

Sections du résumé

BACKGROUND
Injuries in children aged under 5 years most commonly occur in the home and disproportionately affect those living in the most disadvantaged communities. The 'Safe at Home' (SAH) national home safety equipment scheme, which ran in England between 2009 and 2011, has been shown to reduce injury-related hospital admissions, but there is little evidence of cost-effectiveness.
MATERIALS AND METHODS
Cost-effectiveness analysis from a health and local government perspective. Measures were the incremental cost-effectiveness ratio per hospital admission averted (ICER) and cost-offset ratio (COR), comparing SAH expenditure to savings in admission expenditure. The study period was split into three periods: T1 (years 0-2, implementation); T2 (years 3-4) and T3 (years 5-6). Analyses were conducted for T2 versus T1 and T3 versus T1.
RESULTS
Total cost of SAH was £9 518 066. 202 223 hospital admissions in the children occurred during T1-3, costing £3 320 000. Comparing T3 to T1 SAH reduced admission expenditure by £924 per month per local authority and monthly admission rates by 0.5 per local authority per month compared with control areas. ICER per admission averted was £4209 for T3 versus T1, with a COR of £0.29, suggesting that 29p was returned in savings on admission expenditure for every pound spent on SAH.
CONCLUSION
SAH was effective at reducing hospital admissions due to injury and did result in some cost recovery when taking into admissions only. Further analysis of its cost-effectiveness, including emergency healthcare, primary care attendances and wider societal costs, is likely to improve the return on investment further.

Identifiants

pubmed: 36600567
pii: ip-2022-044698
doi: 10.1136/ip-2022-044698
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

158-165

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: MCW, CC and DK previously evaluated the SafeAt Home scheme in a study funded by RoSPA and published in 2011: https://www.rospa.com/rospaweb/docs/advice-services/home-safety/final-evaluation-reportsafe-at-home.pdf. RoSPA received funding from the UK government to manage and implement the Safe At Home scheme.

Auteurs

Matthew Jones (M)

Unit of Lifespan and Population Health, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK matthew.jones3@nottingham.ac.uk.

Trevor Hill (T)

Unit of Lifespan and Population Health, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.

Carol Coupland (C)

Unit of Lifespan and Population Health, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.

Denise Kendrick (D)

Unit of Lifespan and Population Health, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.

Ashley Akbari (A)

Faculty of Medicine, Health, & Life Science, University of Wales Swansea, Swansea, UK.

Sarah Rodgers (S)

Department of Public Health, Policy & Systems, University of Liverpool, Liverpool, UK.

Michael Craig Watson (MC)

Institute of Health Promotion and Education, Lichfield, UK.

Edward Tyrrell (E)

Unit of Lifespan and Population Health, University of Nottingham, Nottingham, UK.

Sheila Merrill (S)

Royal Society for the Prevention of Accidents (RoSPA), Edgbaston, UK.

Ashley Martin (A)

Royal Society for the Prevention of Accidents (RoSPA), Edgbaston, UK.

Elizabeth Orton (E)

Unit of Lifespan and Population Health, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH